Navigation Links
Metamark Genetics, Inc. Announces New Chief Executive Officer
Date:11/5/2010

CAMBRIDGE, Mass., Nov. 5, 2010 /PRNewswire/ -- Metamark Genetics, Inc., a privately held oncology molecular diagnostics company, announced today the appointment of Mark R. Straley as the company's President, Chief Executive Officer, and newest member of its Board of Directors. Kenneth E. Weg, a Metamark co-founder who previously served as interim CEO, will continue to serve as Chairman of the Board of Directors.

Mr. Straley brings twenty five years of experience to Metamark Genetics, Inc., as a proven General Manager with Sales and Marketing expertise in the Global Healthcare Industry. With particular focus on the Diagnostics and Diabetes markets, Mark has a demonstrated track record of increasing revenue and profitability. With both Fortune 100 company and start-up expertise, Mark has operated in multiple healthcare sectors in both developed and emerging markets.

Most recently, Mark was the Worldwide President of Johnson & Johnson's Diagnostics division accountable for $2B in revenue with global responsibility for sales, marketing, customer support and commercial operations. Mark joined Johnson & Johnson in 2005 as the Global Vice President of Marketing for the Diagnostics division. Prior to his assignment with J&J, Mr. Straley worked for such brand name companies as Bayer Healthcare and Abbott Laboratories where he held progressively responsible roles in sales, marketing and general management in several North American locations. Mark is a graduate of Miami University located in Oxford, Ohio with a Bachelor of Science in Marketing.

Kenneth E. Weg, Metamark's Chairman, stated, "Metamark is extremely fortunate to have attracted such a seasoned and successful diagnostics executive to serve as Chief Executive Officer. On behalf of the entire Company and Board of Directors, I welcome Mark to the team and look forward to his leadership."

When commenting on his decision to join Metamark, Mr. Straley stated, "There remains a significant unmet medical need among patients diagnosed with early-stage cancers and their physicians when considering the selection of the most appropriate treatment for that individual patient's tumor. The mission of Metamark is to empower personalized treatment decisions through innovative assays that report on the fundamental molecular determinants of metastatic risk. It is a rare opportunity to be able to join Metamark's team of world-renowned scientific and business leaders in pursuit of this mission."

Cautionary Note Regarding Forward-Looking Statements

This press release, and information contained on Metamark's website, contains forward-looking statements that involve substantial risks and uncertainties, including statements regarding Metamark's strategies and future plans, prospects and results, are forward-looking statements. The words "anticipate," "believe," "expect," "intend," "may," "plan," and other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.  Metamark may not actually achieve the plans or expectations disclosed in its forward-looking statements, and you should not place undue reliance on its forward-looking statements.  


'/>"/>
SOURCE Metamark Genetics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Metamark Genetics, Inc. Announces New Chief Scientific Officer
2. Interleukin Genetics, Inc. Receives Delisting Notification from NYSE Amex
3. deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court
4. Matching Genetics, Technology and Management Practices Critical to Meeting Strong Demand for Agricultural Crops
5. Bolder BioTechnology Announces $1.2 Million in Qualifying Therapeutic Discovery Project Grants
6. Cadence Pharmaceuticals Announces FDA Approval of OFIRMEV™ (acetaminophen) injection for the Management of Pain and Fever
7. IGEN NETWORKS ANNOUNCES THE APPOINTMENT OF TWO NEW MEMBERS TO THE ADVISORY BOARD
8. Elsevier Announces New Partnership With Canadian Cardiovascular Society to Publish the Canadian Journal of Cardiology
9. Advanced Life Sciences Announces US Army Collaboration to Research and Develop Restanza for the Treatment of Malaria
10. QuantaLife Announces Launch of Droplet Digital™ PCR System
11. diaDexus Announces Name Change From VaxGen
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/3/2016)... 2016   ViaCyte, Inc ., a leading, ... stem cell-derived islet replacement therapy for the treatment ... announced that ViaCyte and Janssen Biotech, Inc., one ... Johnson, have agreed to consolidate the assets of ... provides ViaCyte with an exclusive license to all ...
(Date:2/3/2016)... Mass., Feb. 3, 2016 Harvard Apparatus ... biotechnology company developing bioengineered organ implants for life-threatening ... announced that CEO Jim McGorry , will ... Conference on Tuesday, February 9, 2016 at ... City . HART,s presentation will be webcast ...
(Date:2/3/2016)... ... February 03, 2016 , ... StarNet Communications ... solutions today announced the addition of a powerful “Session Preview” feature to its ... current state of the remote Linux desktop or other applications (sessions) they have ...
(Date:2/3/2016)... ... February 03, 2016 , ... ... aid in the rapid development and ongoing quality control of molecular assays targeting ... is extremely high,” Dr. Gregory R. Chiklis, President and CEO of ZeptoMetrix, relayed ...
Breaking Biology Technology:
(Date:1/22/2016)... , January 22, 2016 /PRNewswire/ ... announced the addition of the  "Global ... their offering. --> http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ... the  "Global Behavioral Biometric Market 2016-2020" ... Research and Markets ( http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) ...
(Date:1/20/2016)... Jan. 20, 2016  Synaptics Incorporated (NASDAQ: ... solutions, today announced sampling of S1423, its newest ... and small screen applications including smartwatches, fitness trackers, ... round and rectangular shapes, as well as thick ... with moisture on screen, while wearing gloves, and ...
(Date:1/11/2016)... , Jan. 11, 2016 Synaptics Incorporated ... interface solutions, today announced that its ClearPad ® ... (TDDI) products won two separate categories in the 8 ... Innovator and Best Technology Breakthrough. The Synaptics ® ... a simplified supply chain, thinner devices, brighter displays and ...
Breaking Biology News(10 mins):